BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Janus Pharmaceuticals, Inc. Raises Series A Funding Of Over $2 Million; Funds To Be Used For Clinical Development Of Lead Compounds


10/19/2005 5:13:16 PM

LOS ANGELES--(BUSINESS WIRE)--April 12, 2005--Janus Pharmaceuticals Inc. (Janus) announced the closing of the company's Series A financing round for a total of over $2 million. Lead investor was Private Equity Japan Co., Ltd (PEJ). of Tokyo, Japan. Commensurate with this funding, Mr. Shinji Kimura, Managing Director, PEJ, joins the Janus Board of Directors. Janus currently has three products in development, JA-001, a topical formulation of a widely studied antiviral product for the treatment of shingles (herpes zoster); JA-002, a gel formulation of a novel proprietary antibiotic targeting prevention and treatment of bacterial infections of the skin; and JA-003, an antibiotic cream for the treatment of acne. The proceeds of this funding will be used to complete milestone obligations and further product development activities including initiating Phase 1 clinical studies of JA-001 mid-year and filing an IND for JA-002 in Quarter 3 of 2005.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES